Lessons Learned: Analysis of Complete Response Letters from FDA

Byron Fitzgerald, Founder of ProGen Search analyzes complete response letters from the FDA. This report takes a deep dive into 202 complete response letters and where therapeutic deficiencies fall and what to consider as you plan, whether due to clinical efficacy concerns, manufacturing challenges, safety data gaps, or regulatory misalignment.

Click here for the 202 CRL Rejection Analysis